Mucosis, a Dutch clinical-stage biotechnology company developing mucosal vaccines, has promoted Thomas Johnston to chief executive.
Johnston joined the Groningen-based firm as chief business officer in May 2011, and succeeds Govert Schouten who is leaving the company to found an Internet start-up.
Johnston has more than 15 years of leadership experience in the biotech and other industries and played a lead role in the ongoing rollout of Mucosis’s Mimopath platform licensing initiative and the development of the firm’s strategies for continued growth.
Schouten has been ceo for the past four years during which time he helped transform Mucosis from a start-up into a clinical-stage biotech company with a strong technology and product pipeline.
Johnston joined Mucosis from Novavax, where he was vp of strategy. Prior to this he was a consultant in a number of industries including biotech, and held various senior positions with organisations such as Comcast, Microsoft, and Schlumberger.
